Citation | Zak, M; Mendonca, R; Balazs, M; Barrett, K; Bergeron, P; Blair, WS; Chang, C; Deshmukh, G; Devoss, J; Dragovich, PS; Eigenbrot, C; Ghilardi, N; Gibbons, P; Gradl, S; Hamman, C; Hanan, EJ; Harstad, E; Hewitt, PR; Hurley, CA; Jin, T; Johnson, A; Johnson, T; Kenny, JR; Koehler, MF; Bir Kohli, P; Kulagowski, JJ; Labadie, S; Liao, J; Liimatta, M; Lin, Z; Lupardus, PJ; Maxey, RJ; Murray, JM; Pulk, R; Rodriguez, M; Savage, S; Shia, S; Steffek, M; Ubhayakar, S; Ultsch, M; van Abbema, A; Ward, SI; Xiao, L; Xiao, Y Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. J Med Chem55:6176-93 (2012) [PubMed] Article |
---|
SMILES | COC(=O)N[C@H]1CC[C@@H](CC1)n1c(C)nc2cnc3[nH]ccc3c12 |r,wU:5.4,wD:8.11,(17.33,-10.61,;15.8,-10.54,;14.97,-11.83,;13.43,-11.76,;15.74,-13.16,;14.98,-14.5,;15.73,-15.84,;14.96,-17.17,;13.42,-17.16,;12.65,-15.81,;13.44,-14.49,;12.63,-18.48,;11.09,-18.35,;10.3,-17.03,;10.49,-19.77,;11.66,-20.78,;11.69,-22.31,;13.03,-23.07,;14.35,-22.27,;15.82,-22.72,;16.71,-21.46,;15.78,-20.23,;14.32,-20.73,;12.97,-19.98,)| |